JP2003531590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531590A5 JP2003531590A5 JP2001577426A JP2001577426A JP2003531590A5 JP 2003531590 A5 JP2003531590 A5 JP 2003531590A5 JP 2001577426 A JP2001577426 A JP 2001577426A JP 2001577426 A JP2001577426 A JP 2001577426A JP 2003531590 A5 JP2003531590 A5 JP 2003531590A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- promoter
- sequence
- primer
- flanked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000295 complement Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 102100007493 CNTF Human genes 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- -1 IL -11 Proteins 0.000 description 1
- 102100013277 IRF1 Human genes 0.000 description 1
- 101700001416 IRF1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102100011646 LIF Human genes 0.000 description 1
- 101700037605 LIF Proteins 0.000 description 1
- 102100019388 SOAT1 Human genes 0.000 description 1
- 101700025022 SOAT1 Proteins 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 108091008007 nuclear receptors type I Proteins 0.000 description 1
- 101710028406 satA Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Description
好ましい実施形態においては、治療用タンパク質と特異的に結合し、アルブミン融合タンパク質の治療用タンパク質部分に対応する、抗体のフラグメントもしくは変異体は、(Gly4Ser)3などのペプチドリンカーによって治療用タンパク質のVLドメインと連結された、治療用タンパク質のVHドメインを含んでなるscFvを含んでなるか、またはそのscFvから構成されている(配列番号72)。
天然に存在するシグナル配列を用いて本発明のアルブミン融合タンパク質を産生する場合、pC4は第2のシグナルペプチドを必要としない。このほか、天然に存在するシグナル配列を使用しない場合には、ベクターは異種シグナル配列が含まれるように改変することができる。(たとえば、国際公開WO 96/34891号を参照されたい)
ヒトIgG Fc領域:
GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (配列番号73)
ヒトIgG Fc領域:
GGGATCCGGAGCCCAAATCTTCTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGTGGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (配列番号73)
Jakは、以下の表によりまとめられる多種多様な受容体によって活性化される。(Schidler and Darnell, Ann. Rev. Biochem. 64:621-51(1995)によるレビューから抜粋編集)。Jakを活性化しうるサイトカイン受容体ファミリーは、2つのグループに分けられる:(a)クラス1は、IL-2、IL-3、IL-4、IL-6、IL-7、IL-9、IL-11、IL-12、IL-15、Epo、PRL、GH、G-CSF、GM-CSF、LIF、CNTF、およびトロンボポエチンに対する受容体を含み;そして(b)クラス2は、IFN-a、IFN-g、およびIL-10を含む。クラス1受容体は、保存されたシステインモチーフ(4つの保存されたシステインおよび1つのトリプトファンのセット)およびWSXWSモチーフ(Trp-Ser-Xaa-Trp-Ser(配列番号74)をコードする膜近接領域)を共有する。
実施例32〜33に記載の生物学的アッセイに使用されるプロモーターエレメント含有合成GASを構築するために、PCRに基づくストラテジーを利用してGAS-SV40プロモーター配列を作製する。5'プライマーには、IRF1プロモーター中に見いだされ、一定範囲のサイトカインによる誘導を受けるとSTATに結合することが既に実証されている、GAS結合部位の4つのタンデムコピーが含まれるが(Rothman et al., Immunity 1:457-468(1994))、他のGASまたはISREエレメントを代わりに使用することもできる。5'プライマーはまた、SV40初期プロモーター配列に相補的な18bpの配列を含み、そしてXhoI部位でフランキングされている。5'プライマーの配列は次のとおりである。
5’:GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3’ (配列番号75)
5’:GCGCCTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAG:3’ (配列番号75)
下流プライマーは、SV40プロモーターに相補的であり、そしてHindIII部位でフランキングされている: 5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (配列番号76)。
Clontechから入手したB-gal:プロモータープラスミド中に存在するSV40プロモーター鋳型を用いてPCR増幅を行う。得られたPCR断片をXhoI/Hind IIIで消化させ、そしてBLSK2-.(Stratagene)中にサブクローン化する。フォワードおよびリバースプライマーを用いる配列決定により、インサートが以下の配列を含有することを確認する。
5’:CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3’ (配列番号77)
5’:CTCGAGATTTCCCCGAAATCTAGATTTCCCCGAAATGATTTCCCCGAAATGATTTCCCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3’ (配列番号77)
5’ GCGCTCGAGGGATGACAGCGATAGAACCCCGG-3' (配列番号78)
5’ GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (配列番号79)
5’ GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (配列番号79)
NF-KBプロモーターエレメントを含むベクターを構築するために、PCRに基づいたストラテジーを利用する。上流プライマーは、NF-KB結合部位(GGGGACTTTCCC)(配列番号80)の4つのタンデムコピー、SV40初期プロモーター配列の5'末端に相補的な18bpの配列を含み、そしてXhoI部位でフランキングされている。
5’:GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCCTGCCATCTCAATTAG:3’ (配列番号81)
下流プライマーは、SV40プロモーターの3'末端に相補的であり、そしてHindIII部位でフランキングされている。
5’:GCGGCAAGCTTTTTGCAAAGCCTAGGC:3’ (配列番号76)
5’:GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCCTGCCATCTCAATTAG:3’ (配列番号81)
下流プライマーは、SV40プロモーターの3'末端に相補的であり、そしてHindIII部位でフランキングされている。
5’:GCGGCAAGCTTTTTGCAAAGCCTAGGC:3’ (配列番号76)
Clontechから入手したpB-gal:プロモータープラスミドに存在するSV40プロモーター鋳型を使用して、PCR増幅を行う。得られたPCR断片をXhoIおよびHindIIIで消化し、BLSK2-(Stratagene)にサブクローン化する。T7およびT3プライマーを用いる配列決定により、インサートが以下の配列を含むことを確認する。
5’:CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3’ (配列番号82)
5’:CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCCATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTT:3’ (配列番号82)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22935800P | 2000-04-12 | 2000-04-12 | |
US60/229,358 | 2000-04-12 | ||
US19938400P | 2000-04-25 | 2000-04-25 | |
US60/199,384 | 2000-04-25 | ||
US25693100P | 2000-12-21 | 2000-12-21 | |
US60/256,931 | 2000-12-21 | ||
PCT/US2001/011850 WO2001079442A2 (en) | 2000-04-12 | 2001-04-12 | Albumin fusion proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2003531590A JP2003531590A (ja) | 2003-10-28 |
JP2003531590A5 true JP2003531590A5 (ja) | 2006-03-16 |
Family
ID=27394014
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001576855A Pending JP2003530838A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001576866A Pending JP2003530839A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577463A Pending JP2003530852A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577427A Pending JP2003530846A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577426A Pending JP2003531590A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001575607A Pending JP2004506407A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577428A Pending JP2003530847A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2011109620A Pending JP2011217750A (ja) | 2000-04-12 | 2011-05-16 | アルブミン融合タンパク質 |
JP2013216509A Pending JP2014057589A (ja) | 2000-04-12 | 2013-10-17 | アルブミン融合タンパク質 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001576855A Pending JP2003530838A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001576866A Pending JP2003530839A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577463A Pending JP2003530852A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577427A Pending JP2003530846A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001575607A Pending JP2004506407A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2001577428A Pending JP2003530847A (ja) | 2000-04-12 | 2001-04-12 | アルブミン融合タンパク質 |
JP2011109620A Pending JP2011217750A (ja) | 2000-04-12 | 2011-05-16 | アルブミン融合タンパク質 |
JP2013216509A Pending JP2014057589A (ja) | 2000-04-12 | 2013-10-17 | アルブミン融合タンパク質 |
Country Status (10)
Country | Link |
---|---|
US (23) | US6994857B2 (ja) |
EP (21) | EP2275557A1 (ja) |
JP (9) | JP2003530838A (ja) |
AU (7) | AU2001259063A1 (ja) |
BE (1) | BE2016C059I2 (ja) |
CA (8) | CA2405525A1 (ja) |
DK (2) | DK2216409T3 (ja) |
ES (2) | ES2529300T3 (ja) |
FR (1) | FR16C0043I2 (ja) |
WO (7) | WO2001079444A2 (ja) |
Families Citing this family (641)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
WO2002024719A1 (en) * | 2000-09-20 | 2002-03-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US20030032102A1 (en) * | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1088084B1 (en) * | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
US20050181482A1 (en) * | 2004-02-12 | 2005-08-18 | Meade Harry M. | Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk |
US20040199099A1 (en) * | 1998-07-10 | 2004-10-07 | Matson James R | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease |
US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
AU773428B2 (en) | 1998-10-13 | 2004-05-27 | Peptide Biosciences, Inc. | Stabilized bioactive peptides and methods of identification, synthesis and use |
NZ515329A (en) * | 1999-05-05 | 2004-05-28 | Tvw Telethon Inst Child Health | Isolating biological modulators from biodiverse gene fragment libraries |
US6946129B1 (en) * | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
CA2388822A1 (en) * | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
EP1235845A4 (en) * | 1999-11-05 | 2003-06-25 | Human Genome Sciences Inc | 24 HUMAN SECRETED PROTEINS |
AU1449001A (en) * | 1999-11-05 | 2001-06-06 | Human Genome Sciences, Inc. | 28 human secreted proteins |
JP2003520031A (ja) * | 1999-11-12 | 2003-07-02 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 28個のヒト分泌タンパク質 |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
EP1240337B1 (en) | 1999-12-24 | 2006-08-23 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
US7534417B2 (en) | 2000-02-24 | 2009-05-19 | Agensys, Inc. | 103P2D6: tissue specific protein highly expressed in various cancers |
US7291122B2 (en) * | 2000-03-24 | 2007-11-06 | Immunocept, L.L.C. | Hemofiltration methods for treatment of diseases in a mammal |
JP2003530838A (ja) * | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US20030143654A1 (en) * | 2000-05-12 | 2003-07-31 | Matthias Grell | F-box containing protein |
US6787040B2 (en) * | 2000-05-16 | 2004-09-07 | Immunocept, L.L.C. | Method and system for colloid exchange therapy |
WO2001090179A2 (en) * | 2000-05-23 | 2001-11-29 | Lexicon Genetics Incorporated | Novel human thrombospondin-like proteins and polynucleotides encoding the same |
ATE385504T1 (de) | 2000-06-06 | 2008-02-15 | Bristol Myers Squibb Co | Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung |
JP2004500862A (ja) * | 2000-06-08 | 2004-01-15 | インサイト・ゲノミックス・インコーポレイテッド | 細胞内シグナル伝達タンパク質 |
EP1294871A1 (en) * | 2000-06-21 | 2003-03-26 | Amgen, Inc. | Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
CA2419306A1 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | 23 human secreted proteins |
CA2418676A1 (en) * | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | 21 human secreted proteins |
AU2001229509A1 (en) * | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | 11 human secreted proteins |
EP1313761A4 (en) * | 2000-08-28 | 2005-01-26 | Human Genome Sciences Inc | 18 HUMAN SECRETED PROTEINS |
AU2001227920A1 (en) * | 2000-09-29 | 2002-04-15 | Human Genome Sciences, Inc. | 24 human secreted proteins |
AU2001296235A1 (en) * | 2000-10-12 | 2002-04-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
US6949371B2 (en) | 2000-10-20 | 2005-09-27 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
FR2815964A1 (fr) * | 2000-10-30 | 2002-05-03 | Inst Nat Sante Rech Med | Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications |
AU2002239229A1 (en) | 2000-12-05 | 2002-06-18 | Wisconsin Alumni Research Foundation | Receptor for b. anthracis toxin |
JP2004528014A (ja) | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Glp−1融合タンパク質 |
US20030148920A1 (en) * | 2000-12-27 | 2003-08-07 | Steven Rosen | Sulfatases and methods of use thereof |
JP4344519B2 (ja) * | 2000-12-28 | 2009-10-14 | 旭化成ファーマ株式会社 | NF−κB活性化遺伝子 |
EP1368468A4 (en) * | 2001-02-23 | 2005-02-16 | Human Genome Sciences Inc | 83 HUMAN SECRETED PROTEINS |
CA2441006A1 (en) * | 2001-03-08 | 2002-09-19 | Hyseq, Inc. | Methods and materials relating to fibulin-like polypeptides and polynucleotides |
WO2002083921A2 (en) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7164007B2 (en) | 2001-06-20 | 2007-01-16 | Genentech, Inc. | Anti-PR020044 antibodies |
WO2003005033A2 (en) * | 2001-07-06 | 2003-01-16 | Geneprot, Inc. | Carcinoma-related peptides |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE10251673A1 (de) | 2001-11-09 | 2003-07-10 | Hoffmann La Roche | Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms |
KR100406760B1 (ko) * | 2001-11-16 | 2003-11-21 | 신코엠 주식회사 | 반도체 메모리 장치 |
IL162600A0 (en) | 2001-12-17 | 2005-11-20 | Applied Research Systems | Cc-chemokine mutants as cc-chemokine antagonists |
US20040082761A1 (en) * | 2001-12-18 | 2004-04-29 | Duggan Brendan M. | Cell adhesion proteins |
CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20060253913A1 (en) * | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
CA2471363C (en) * | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7081446B2 (en) * | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
AU2003244516A1 (en) * | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Hiv inhibiting proteins |
US20050222023A1 (en) * | 2002-02-07 | 2005-10-06 | Hans-Peter Hauser | Albumin-fused kunitz domain peptides |
US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
KR20040096592A (ko) * | 2002-02-21 | 2004-11-16 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
CA2477614A1 (en) * | 2002-03-05 | 2003-09-18 | Merck & Co., Inc. | Biomarker for efficacy of appetite suppressant drugs |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US20070015230A1 (en) * | 2002-04-15 | 2007-01-18 | Hammond David J | Identification and characterization of analytes from whole blood |
US7217507B2 (en) * | 2002-04-15 | 2007-05-15 | The American National Red Cross | Method for detecting ligands and targets in a mixture |
EP1490108A4 (en) | 2002-04-18 | 2006-08-09 | Gen Hospital Corp | DRAG11 GENERAL FAMILY (DRAGON) |
US7141381B2 (en) | 2002-04-25 | 2006-11-28 | Bristol-Myers Squibb Company | Human leucine-rich repeat-containing proteins specifically expressed in the nervous system |
GB0210464D0 (en) | 2002-05-08 | 2002-06-12 | Svanborg Catharina | Therapeutic treatment |
ES2381265T3 (es) * | 2002-06-07 | 2012-05-24 | Zymogenetics, Inc. | Uso de IL-21 y anticuerpo monoclonal para tratar cánceres sólidos |
PT2311432E (pt) | 2002-06-07 | 2015-02-09 | Dyax Corp | Polipeptídeos de domínio kunitz modificado e sua utilização para a redução de isquemia ou aparecimento de uma resposta inflamatória sistémica associada a um procedimento cirúrgico |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
CN101172091B (zh) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
AU2003245089A1 (en) * | 2002-07-03 | 2004-01-23 | Nexgen Biotechnologies, Inc. | Fusion polypeptide comprising epidermal growth factor and human serum albumin |
US20040138114A1 (en) * | 2002-07-08 | 2004-07-15 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1541586A4 (en) * | 2002-07-22 | 2006-08-09 | Astellas Pharma Inc | NEW GENE ASSOCIATED WITH RHEUMATOID ARTHRITIS |
GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
JP2005534330A (ja) * | 2002-08-07 | 2005-11-17 | デルタ バイオテクノロジー リミテッド | アルブミン融合繊毛様神経栄養因子 |
US20060129082A1 (en) * | 2002-08-13 | 2006-06-15 | Jacek Rozga | Selective plasma exchange therapy |
DK1542710T3 (da) | 2002-08-28 | 2012-10-15 | Dyax Corp | Fremgangsmåde til konservering af organer og væv |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
WO2004022096A1 (en) * | 2002-09-06 | 2004-03-18 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
JP2006504694A (ja) * | 2002-09-18 | 2006-02-09 | サントル・オスピタリエ・ドゥ・リュニヴェルシテ・ドゥ・モントリオール・(シー・エイチ・ユー・エム) | Ghrh類似体 |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2003292273A1 (en) * | 2002-12-20 | 2004-07-14 | Karolinska Institutet Innovations Ab | Asthma susceptibility locus |
KR20050085881A (ko) * | 2002-12-26 | 2005-08-29 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 단백질 및 그 용도 |
NZ570201A (en) * | 2003-02-11 | 2011-03-31 | Shire Human Genetic Therapies | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge) |
US7381410B2 (en) * | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
AU2004220525B2 (en) * | 2003-03-12 | 2011-03-31 | Vasgene Therapeutics, Inc. | Nucleic acid compounds for inhibiting angiogenesis and tumor growth |
WO2004082640A2 (en) * | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
CN1798770B (zh) * | 2003-04-04 | 2010-06-09 | 洛桑大学 | 用于治疗癌症的多聚肽体 |
EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
WO2004094589A2 (en) * | 2003-04-18 | 2004-11-04 | Incyte Corporation | Secreted proteins |
WO2004101620A2 (en) * | 2003-05-01 | 2004-11-25 | Compound Therapeutics, Inc. | Serum albumin scaffold-based proteins and uses thereof |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
WO2005001093A1 (ja) * | 2003-06-30 | 2005-01-06 | Nihon University | 細胞外基質沈着タンパク質 |
AU2004259727A1 (en) | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases. |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
GB0320877D0 (en) * | 2003-09-05 | 2003-10-08 | Celltech R&D Ltd | A protein involved in carcinoma |
EP1682178B8 (en) | 2003-11-04 | 2010-09-01 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for cancers expressing the cd40 antigen |
ES2380022T3 (es) * | 2003-12-03 | 2012-05-07 | Monika KRÖZ | Proteínas de fusión a interleucina-11 |
CN100379762C (zh) * | 2003-12-08 | 2008-04-09 | 中国人民解放军军事医学科学院生物工程研究所 | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 |
US9050378B2 (en) | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US7371381B2 (en) | 2003-12-12 | 2008-05-13 | Amgen Inc. | Anti-galanin antibodies and uses thereof |
GB0329722D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
CA2551546A1 (en) * | 2003-12-24 | 2005-07-07 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
NZ548612A (en) | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
SE0400489D0 (sv) * | 2004-02-27 | 2004-02-27 | Biovitrum Ab | Therapeutic proteins |
ATE458834T1 (de) * | 2004-03-03 | 2010-03-15 | Evotec Neurosciences Gmbh | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten |
US20050201959A1 (en) * | 2004-03-11 | 2005-09-15 | Vvii Newco 2003, Inc. | Methods and compositions for altering skin coloration |
JP2007528393A (ja) * | 2004-03-11 | 2007-10-11 | カイセラ バイオファーマシューティカルズ, インコーポレイテッド | 皮膚の状態および毛の状態を予防および処置するための組成物および方法 |
KR20070034465A (ko) | 2004-03-12 | 2007-03-28 | 바스진 테라퓨틱스, 인크. | 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물 |
JP2007532666A (ja) | 2004-04-14 | 2007-11-15 | アヴィリッド インコーポレーテッド | ウイルス核酸を対象とした修飾ヌクレアーゼを用いた組成物及びウイルス性疾患の予防並びに治療方法 |
PL1745078T3 (pl) * | 2004-04-23 | 2009-12-31 | Conjuchem Biotechnologies Inc | Sposób oczyszczania koniugatów albumin |
KR100599454B1 (ko) * | 2004-04-27 | 2006-07-12 | 재단법인서울대학교산학협력재단 | 종양 억제자로 작용하는 aim3의 신규 용도 |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1756554A4 (en) * | 2004-06-03 | 2009-04-29 | Vermillion Inc | BIOMARKERS FOR PERIPHERAL ARTERY DISEASE |
WO2006009825A1 (en) * | 2004-06-17 | 2006-01-26 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
WO2006019904A1 (en) | 2004-07-14 | 2006-02-23 | University Of Utha Research Foundation | Netrin-related compositions and uses |
JP2008509673A (ja) * | 2004-08-13 | 2008-04-03 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 |
US7700720B2 (en) | 2004-09-21 | 2010-04-20 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
EP1799713B1 (en) * | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20060078541A1 (en) * | 2004-10-01 | 2006-04-13 | Giles Brian C | Method and formula for stem cells' stimulation, targeting release, trafficking and homing |
US7892540B2 (en) | 2004-10-06 | 2011-02-22 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
WO2006042197A2 (en) * | 2004-10-11 | 2006-04-20 | The Board Of Trustees Of The Leland Standford Junior University | Use of del-1 in hair, bone and cartilage regeneration |
KR101310511B1 (ko) | 2004-10-25 | 2013-09-25 | 임뮨 시스템 키 리미티드 | 흉선-특이성 단백질 |
KR100583350B1 (ko) * | 2004-11-03 | 2006-06-05 | (주)넥스젠 | Fas-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법 |
MX2007005327A (es) * | 2004-11-09 | 2007-08-02 | Ares Trading Sa | Metodo para purificacion de la hormona foliculo estimulante (hfe). |
DK2330200T3 (en) | 2004-12-23 | 2017-07-24 | Albumedix As | GENE EXPRESSION TECHNIQUE |
EP3072522B1 (en) | 2005-01-06 | 2019-04-24 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
US20060178301A1 (en) * | 2005-02-04 | 2006-08-10 | Mathias Jurs | Albumin-fused ciliary neurotrophic factor |
PL1853718T3 (pl) | 2005-02-15 | 2016-01-29 | Univ Duke | Przeciwciała anty-CD19 i zastosowania w onkologii |
US20110230407A1 (en) * | 2005-03-14 | 2011-09-22 | Alexander Yuzhakov | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma |
US20060240488A1 (en) * | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of an immune response to GDF-8 modulating agents |
MX2007011400A (es) * | 2005-03-23 | 2007-10-11 | Wyeth Corp | Deteccion de agentes moduladores de crecimiento y la diferenciacion del factor 8 (gdf 8). |
RU2412199C2 (ru) | 2005-04-18 | 2011-02-20 | Ново Нордиск А/С | Варианты ил-21 |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
JP5129122B2 (ja) | 2005-04-26 | 2013-01-23 | トリオン ファーマ ゲーエムベーハー | 癌治療のための抗体およびグルココルチコイドの組み合わせ |
US9585932B2 (en) | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
US9345745B2 (en) * | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
JP5047947B2 (ja) | 2005-05-05 | 2012-10-10 | デューク ユニバーシティ | 自己免疫疾患のための抗cd19抗体治療 |
JP2008546426A (ja) * | 2005-05-12 | 2008-12-25 | ザイモジェネティクス, インコーポレイテッド | T細胞を共刺激するためにpHHLA2を使用する方法 |
NZ564243A (en) | 2005-06-08 | 2011-03-31 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1) pathway |
WO2007014167A2 (en) * | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions for and methods of treating epithelial diseases with growth factors |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
SG155183A1 (en) * | 2005-08-26 | 2009-09-30 | Ares Trading Sa | Process for the preparation of glycosylated interferon beta |
US7713715B2 (en) * | 2005-09-06 | 2010-05-11 | University Of Tennessee Research Foundation | Method for diagnosing infections |
US20070191272A1 (en) * | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
US7846445B2 (en) * | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
US20090099031A1 (en) * | 2005-09-27 | 2009-04-16 | Stemmer Willem P | Genetic package and uses thereof |
US20080274096A1 (en) * | 2005-10-03 | 2008-11-06 | Astrazeneca Ab | Fusion Proteins Having a Modulated Half-Life in Plasma |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
AU2006323925B2 (en) * | 2005-12-09 | 2012-08-02 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
KR20080079301A (ko) * | 2005-12-09 | 2008-08-29 | 시애틀 지네틱스, 인크. | Cd40 결합제를 이용하는 방법 |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
JP2009520469A (ja) * | 2005-12-22 | 2009-05-28 | コンジュクヘム ビオテクフノロギエス インコーポレイテッド | アルブミンと治療薬との前もって形成された抱合体の産生のための方法 |
US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
US20100015642A1 (en) * | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
WO2007084568A2 (en) | 2006-01-17 | 2007-07-26 | Health Research, Inc. | Heteroduplex tracking assay |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007097961A1 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye & Ear Infirmary | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2004689A4 (en) | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | PURIFICATION OF ANTIBODIES |
KR101492422B1 (ko) * | 2006-04-11 | 2015-02-12 | 체에스엘 베링 게엠베하 | 치료용 폴리펩타이드의 생체내 회수율을 증가시키는 방법 |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
WO2007146038A2 (en) * | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
AU2013202566C1 (en) * | 2006-06-14 | 2018-07-12 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
AU2007274035A1 (en) * | 2006-07-13 | 2008-01-17 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
CA2658654A1 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
US20090208480A1 (en) * | 2006-08-04 | 2009-08-20 | Yue Huang | Long half-life recombinant butyrylcholinesterase |
AU2007292295B2 (en) * | 2006-09-06 | 2013-06-06 | Immunoforge Co., Ltd. | Fusion peptide therapeutic compositions |
EP2069396B1 (en) | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
US10925977B2 (en) | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
WO2008049920A2 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | Il-21 variants |
US20100136028A1 (en) | 2006-11-07 | 2010-06-03 | Sparrow Carl P | Antagonists of pcsk9 |
ES2535358T3 (es) | 2006-12-12 | 2015-05-08 | Biorexis Pharmaceutical Corporation | Bibliotecas de proteínas de fusión de transferrina |
EP2557090A3 (en) | 2006-12-19 | 2013-05-29 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
JP5448839B2 (ja) * | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | インビボで長い半減期を有する修飾された凝固因子 |
EP2423222B2 (en) | 2007-01-30 | 2020-07-29 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
US8283319B2 (en) | 2007-02-12 | 2012-10-09 | Csl Behring Gmbh | Therapeutic application of Kazal-type serine protease inhibitors |
WO2008118386A2 (en) | 2007-03-27 | 2008-10-02 | Merck & Co., Inc. | Method for detecting autoprocessed, secreted pcsk9 |
WO2008137915A2 (en) | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2068927B1 (en) | 2007-05-14 | 2015-10-21 | MedImmune, LLC | Methods of reducing eosinophil levels |
CA2840407A1 (en) * | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
AU2008275911A1 (en) * | 2007-07-19 | 2009-01-22 | Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University | Self- anchoring MEMS intrafascicular neural electrode |
KR20100058541A (ko) * | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
UA117446C2 (uk) | 2007-08-29 | 2018-08-10 | Санофі-Авентіс | Гуманізоване антитіло до cxcr5 |
JP2009055838A (ja) * | 2007-08-31 | 2009-03-19 | Nipro Corp | 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物 |
MX349306B (es) * | 2007-09-21 | 2017-07-19 | Univ California | Interferón de objetivo demuestra actividades potentes apoptóticas y antitumorales. |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2011500756A (ja) * | 2007-10-22 | 2011-01-06 | メルク セローノ ソシエテ アノニム | Fc融合タンパク質を精製する方法 |
US20100256337A1 (en) * | 2007-10-22 | 2010-10-07 | Merck Serono Sa | Method for purifying an fc-containing protein |
EP2225275A4 (en) | 2007-11-28 | 2013-04-03 | Medimmune Llc | PROTEIN FORMULATION |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
EP2245064B1 (en) | 2007-12-21 | 2014-07-23 | Medimmune Limited | BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ralpha) |
US20100311072A1 (en) * | 2008-01-28 | 2010-12-09 | Bristol-Myers Squibb Company | Fluorescence polarization binding assay for characterizing glucokinase ligands |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
US20110020325A1 (en) * | 2008-02-29 | 2011-01-27 | Kwon Eugene D | Methods for reducing granulomatous inflammation |
JP5020135B2 (ja) * | 2008-03-19 | 2012-09-05 | ソニーモバイルコミュニケーションズ, エービー | 携帯端末装置およびコンピュータプログラム |
EP2262539B1 (en) | 2008-04-01 | 2015-07-15 | Novo Nordisk A/S | Insulin albumin conjugates |
EP2260058A2 (en) | 2008-04-07 | 2010-12-15 | Ablynx N.V. | Single variable domains against the notch pathways |
EP3173424A1 (en) | 2008-05-02 | 2017-05-31 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
CN103739712B (zh) * | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
AU2013202564B2 (en) * | 2008-06-24 | 2015-09-17 | Csl Behring Gmbh | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life |
WO2009158704A2 (en) | 2008-06-27 | 2009-12-30 | Duke University | Therapeutic agents comprising elastin-like peptides |
CN102149379A (zh) | 2008-07-10 | 2011-08-10 | 安吉翁生物医药有限公司 | 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物 |
US9034325B2 (en) | 2008-07-22 | 2015-05-19 | Ablynx N.V. | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
MY159396A (en) | 2008-08-05 | 2016-12-30 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
US20110223188A1 (en) * | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
JP5611210B2 (ja) | 2008-09-07 | 2014-10-22 | グリコネックス インコーポレイテッド | 抗拡張i型スフィンゴ糖脂質抗体、その誘導体および使用 |
EP2358392B1 (en) | 2008-11-12 | 2019-01-09 | MedImmune, LLC | Antibody formulation |
BRPI0921586A2 (pt) | 2008-11-18 | 2019-09-24 | Merrimack Pharmaceuticals Inc | articuladores de albumina de soro humana e conjugados destes |
CA2744449C (en) | 2008-11-28 | 2019-01-29 | Emory University | Methods for the treatment of infections and tumors |
KR20210060670A (ko) * | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
US8748115B2 (en) | 2008-12-12 | 2014-06-10 | Merck Sharp & Dohme Corp. | PCSK9 immunoassay |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
KR20110132327A (ko) | 2009-01-16 | 2011-12-07 | 테바 파마슈티컬 인더스트리즈 리미티드 | 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형 |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
ES2730800T3 (es) * | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
EP3243835B1 (en) | 2009-02-11 | 2024-04-10 | Albumedix Ltd | Albumin variants and conjugates |
US20120121591A1 (en) | 2009-03-20 | 2012-05-17 | Amgen Inc. | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 |
US9403898B2 (en) | 2009-05-07 | 2016-08-02 | Novozymes Biopharma Dk A/S | Method for purifying albumin |
EP2258398A1 (en) * | 2009-05-26 | 2010-12-08 | Araclón Biotech, S. L. | Albumin-amyloid peptide conjugates and uses thereof |
US11512326B2 (en) * | 2009-05-26 | 2022-11-29 | University Of Florida Research Foundation, Incorporated | Small angiotensin peptide expression system in mammalian cells |
DK2440228T3 (en) | 2009-06-08 | 2018-12-17 | Amunix Operating Inc | Glucose regulating polypeptides and methods for their preparation and use |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN101628346B (zh) * | 2009-07-25 | 2012-05-16 | 大连理工大学 | 一种减缓碳纤维复合材料手工制孔出口速度的方法及其缓冲装置 |
EP3381937A3 (en) | 2009-08-13 | 2018-10-31 | The Johns Hopkins University | Methods of modulating immune function |
US20120148557A1 (en) | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
US20110202016A1 (en) * | 2009-08-24 | 2011-08-18 | Arsenal Medical, Inc. | Systems and methods relating to polymer foams |
US9044580B2 (en) | 2009-08-24 | 2015-06-02 | Arsenal Medical, Inc. | In-situ forming foams with outer layer |
US9173817B2 (en) | 2009-08-24 | 2015-11-03 | Arsenal Medical, Inc. | In situ forming hemostatic foam implants |
AU2010290131C1 (en) | 2009-08-24 | 2015-12-03 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
US10420862B2 (en) | 2009-08-24 | 2019-09-24 | Aresenal AAA, LLC. | In-situ forming foams for treatment of aneurysms |
US8451450B2 (en) * | 2009-09-14 | 2013-05-28 | Bio-Rad Laboratories, Inc. | Near real time optical phase conjugation |
US20110195494A1 (en) | 2009-10-02 | 2011-08-11 | Boehringer Ingelheim International Gmbh | Dll4-binging molecules |
US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
AU2010303415B2 (en) | 2009-10-07 | 2015-02-19 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US20120322075A1 (en) * | 2009-10-26 | 2012-12-20 | Externautics S.P.A. | Lung Tumor Markers and Methods of Use Thereof |
GB2488077A (en) | 2009-10-30 | 2012-08-15 | Novozymes Biopharma Dk As | Albumin variants |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
JP2013509194A (ja) | 2009-10-30 | 2013-03-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Ax213およびax132pcsk9アンタゴニストおよびバリアント |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US8680233B2 (en) * | 2009-11-17 | 2014-03-25 | Valorisation-Recherche, Limited Partnership | Heteropeptides useful for reducing nonspecific adsorption |
CA2782424C (en) * | 2009-12-06 | 2021-07-27 | Biogen Idec Hemophilia Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
CN102711795A (zh) | 2009-12-08 | 2012-10-03 | 泰华制药工业有限公司 | 用于治疗可卡因滥用的BChE白蛋白融合体 |
US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
AU2010340358B2 (en) | 2009-12-21 | 2014-07-24 | Pharmathene, Inc. | Recombinant butyrylcholinesterases and truncates thereof |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
CA2787895A1 (en) | 2010-01-22 | 2011-07-28 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
MX345736B (es) | 2010-01-22 | 2017-02-14 | Novo Nordisk Healthcare Ag | Hormonas de crecimiento con eficacia in vivo prolongada. |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
US8592364B2 (en) * | 2010-02-11 | 2013-11-26 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | CCR7 ligand delivery and co-delivery in immunotherapy |
CN102781962B (zh) | 2010-03-03 | 2014-12-10 | 阿布林克斯公司 | 双互补位A-β结合多肽 |
EP2371857A1 (en) | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
JP5969458B2 (ja) | 2010-04-09 | 2016-08-17 | アルブミディクス アクティーゼルスカブ | アルブミン誘導体及び変異体 |
BR112012028306A2 (pt) | 2010-05-06 | 2020-11-03 | Novartis Ag | anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações |
AU2011249782B2 (en) | 2010-05-06 | 2014-10-02 | Novartis Ag | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies |
CN102906118B (zh) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | 与her3相关的生物材料 |
US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
CN103140237A (zh) | 2010-07-09 | 2013-06-05 | 比奥根艾迪克依蒙菲利亚公司 | 因子ix多肽及其使用方法 |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
PT2606070T (pt) | 2010-08-20 | 2017-03-31 | Novartis Ag | Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3) |
AU2011293127B2 (en) | 2010-08-27 | 2016-05-12 | Abbvie Stemcentrx Llc | Notum protein modulators and methods of use |
AU2011295715B9 (en) | 2010-09-03 | 2017-02-23 | Abbvie Stemcentrx Llc | Novel modulators and methods of use |
US20120225081A1 (en) | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
US8993727B2 (en) | 2010-09-22 | 2015-03-31 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
US8853490B2 (en) * | 2010-10-26 | 2014-10-07 | Pioneer Hi Bred International Inc | Antifungal proteins and methods of use |
EP2635598A1 (en) | 2010-11-01 | 2013-09-11 | Novozymes Biopharma DK A/S | Albumin variants |
EP2635607B1 (en) | 2010-11-05 | 2019-09-04 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
WO2012062713A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
US9066974B1 (en) | 2010-11-13 | 2015-06-30 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
US9095606B1 (en) | 2010-11-13 | 2015-08-04 | Sirbal Ltd. | Molecular and herbal combinations for treating psoriasis |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
BR112013014119A8 (pt) | 2010-12-08 | 2017-07-11 | Stem Centrx Inc | Novos moduladores e métodos de uso |
WO2012091138A1 (ja) | 2010-12-28 | 2012-07-05 | 大日本住友製薬株式会社 | アルツハイマー病の診断薬及び診断方法 |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
CN105713092B (zh) | 2011-01-06 | 2019-09-10 | 戴埃克斯有限公司 | 血浆前激肽释放酶结合蛋白 |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
CA2828405A1 (en) | 2011-02-28 | 2012-09-07 | Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale | Apoptosis-inducing molecules and uses therefor |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
PL2683397T3 (pl) | 2011-03-09 | 2018-01-31 | Csl Behring Gmbh | Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
JP2014509859A (ja) | 2011-03-16 | 2014-04-24 | アムジエン・インコーポレーテツド | 17nav1.3およびnav1.7の強力かつ選択的阻害剤 |
AR085911A1 (es) | 2011-03-16 | 2013-11-06 | Sanofi Sa | Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual |
WO2012135500A1 (en) | 2011-03-29 | 2012-10-04 | The General Hospital Corporation | Engineered thioredoxin-like fold proteins |
CA2827787A1 (en) | 2011-03-30 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Anticoagulant antidotes |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
US20130078247A1 (en) | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
JP2014517685A (ja) | 2011-04-15 | 2014-07-24 | コンピュゲン エルティーディー. | 免疫関連疾患およびがんの治療のためのポリペプチドおよびポリヌクレオチドならびにそれらの使用 |
EP2515112B1 (en) * | 2011-04-22 | 2015-08-12 | Sysmex Corporation | Method for electrochemically detecting analyte |
EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
SI2717898T1 (sl) | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
WO2012172495A1 (en) | 2011-06-14 | 2012-12-20 | Novartis Ag | Compositions and methods for antibodies targeting tem8 |
US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
PL2726092T3 (pl) | 2011-06-28 | 2019-11-29 | Inhibrx Lp | Polipeptydy fuzyjne serpiny i sposoby ich stosowania |
US9382305B2 (en) | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
BR112014000042A2 (pt) | 2011-07-05 | 2017-02-21 | Novozymes Biopharma Dk As | composição, meio de cultura celular, uso de uma composição, e, método para cultivar células |
JP2014529293A (ja) | 2011-07-08 | 2014-11-06 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | レラキシンを放出する融合タンパク質およびその使用 |
DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
EP2734239A2 (en) * | 2011-07-18 | 2014-05-28 | Arts Biologics A/S | Long acting luteinizing hormone (lh) compound |
KR102042982B1 (ko) | 2011-07-22 | 2019-11-11 | 체에스엘 베링 게엠베하 | 억제성 항-xii/xiia 인자 모노클로날 항체 및 이들의 사용 |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US8993831B2 (en) * | 2011-11-01 | 2015-03-31 | Arsenal Medical, Inc. | Foam and delivery system for treatment of postpartum hemorrhage |
AU2012332587B2 (en) | 2011-11-01 | 2017-02-23 | Bionomics, Inc. | Antibodies and methods of treating cancer |
AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
ES2666856T3 (es) | 2011-11-04 | 2018-05-08 | Novartis Ag | Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media |
JP6326371B2 (ja) | 2011-11-04 | 2018-05-16 | ザイムワークス,インコーポレイテッド | Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン |
US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
BR112014013412A8 (pt) | 2011-12-05 | 2021-06-08 | Novartis Ag | anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos |
AU2012349736A1 (en) | 2011-12-05 | 2014-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3 |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
CA2859493A1 (en) | 2011-12-21 | 2013-06-27 | Novartis Ag | Compositions and methods for antibodies targeting factor p |
JP6127063B2 (ja) | 2011-12-22 | 2017-05-10 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 中枢神経系の続発性浮腫の治療のためのc1インヒビターの使用 |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
CA2863328A1 (en) | 2012-01-12 | 2013-07-18 | Biogen Idec Ma Inc. | Chimeric factor viii polypeptides and uses thereof |
EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
SI3564260T1 (sl) | 2012-02-15 | 2023-02-28 | Bioverativ Therapeutics Inc. | Sestavki faktorja VIII in postopki njegove izdelave in uporabe |
JP6692602B2 (ja) | 2012-02-15 | 2020-05-13 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 赤血球結合治療剤 |
EP2814502B1 (en) * | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
EP3093294A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
AU2013226340B2 (en) | 2012-02-27 | 2017-06-22 | Ablynx N.V. | CX3CR1-binding polypeptides |
MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
GB201204868D0 (en) * | 2012-03-20 | 2012-05-02 | San Raffaele Centro Fond | Peptides |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
EP2830646B1 (en) | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013163631A2 (en) * | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
ES2843054T3 (es) | 2012-05-10 | 2021-07-15 | Zymeworks Inc | Construcciones heteromultiméricas de cadenas pesadas de inmunoglobulina con mutaciones en el dominio Fc |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
IN2014DN08912A (ja) | 2012-05-30 | 2015-05-22 | Bayer Cropscience Ag | |
NZ701724A (en) | 2012-05-30 | 2016-11-25 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
BR122019010584B1 (pt) | 2012-05-30 | 2020-06-30 | Bayer Cropscience Ag. | composição que compreende um agente de controle biológico e um fungicida, seus usos, semente resistente a patógeno, método para reduzir os danos totais em plantas e em partes de plantas, e kit de partes |
WO2013178658A1 (en) | 2012-05-30 | 2013-12-05 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
US10306889B2 (en) | 2012-05-30 | 2019-06-04 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
CN104507315A (zh) | 2012-05-30 | 2015-04-08 | 拜尔农作物科学股份公司 | 包含生物防治剂和选自呼吸链复合物i或ii抑制剂的杀真菌剂的组合物 |
KR102095974B1 (ko) | 2012-05-30 | 2020-04-02 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 생물학적 방제제 및 살곤충제를 포함하는 조성물 |
CN104507319B (zh) | 2012-05-30 | 2018-08-03 | 拜尔农作物科学股份公司 | 包含生物防治剂和选自脂质膜合成抑制剂、黑素生物合成抑制剂、核酸合成抑制剂或信号转导抑制剂的杀真菌剂的组合物 |
US9596860B2 (en) | 2012-05-30 | 2017-03-21 | Bayer Cropscience Ag | Composition comprising a biological control agent and a fungicide selected from inhibitors of the mitosis and cell division or compounds having a multi-site action |
PL2854547T3 (pl) | 2012-05-30 | 2019-02-28 | Bayer Cropscience Ag | Kompozycja zawierająca środek kontroli biologicznej i trifloksystrobinę |
US9380787B2 (en) | 2012-05-30 | 2016-07-05 | Bayer Cropscience Ag | Composition comprising a biological control agent and a fungicide selected from inhibitors of amino acid or protein biosynthesis, inhibitors of ATP production and inhibitors of the cell wall synthesis |
US9398770B2 (en) | 2012-05-30 | 2016-07-26 | Bayer Cropscience Ag | Compositions comprising a biological control agent and an insecticide |
EP3693000B1 (en) | 2012-06-08 | 2022-03-02 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
EA029685B1 (ru) | 2012-07-11 | 2018-04-30 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты) |
JP6498601B2 (ja) | 2012-07-13 | 2019-04-10 | ザイムワークス,インコーポレイテッド | 多価ヘテロ多量体足場設計および構築物 |
US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
WO2014035475A1 (en) | 2012-09-02 | 2014-03-06 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
CA2890766A1 (en) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
WO2014084859A1 (en) | 2012-11-30 | 2014-06-05 | Novartis Ag | Molecules and methods for modulating tmem16a activities |
CA2893767C (en) | 2012-12-05 | 2022-11-08 | Novartis Ag | Compositions and methods for antibodies targeting epo |
WO2014099984A1 (en) | 2012-12-20 | 2014-06-26 | Amgen Inc. | Apj receptor agonists and uses thereof |
CA2896793A1 (en) | 2013-01-15 | 2014-07-24 | Teva Pharmaceutical Industries Ltd. | Formulations of albu-bche, preparation and uses thereof |
KR101503907B1 (ko) * | 2013-01-17 | 2015-03-20 | 서울대학교산학협력단 | 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신 |
WO2014120619A2 (en) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR20150119022A (ko) | 2013-02-11 | 2015-10-23 | 바이엘 크롭사이언스 엘피 | 고제로틴 및 생물학적 방제제를 포함하는 조성물 |
HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
EP3318124A3 (en) | 2013-02-16 | 2018-05-30 | Albumedix A/S | Pharmacokinetic animal model |
JP6289511B2 (ja) | 2013-02-28 | 2018-03-07 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 羊水塞栓の治療剤 |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
EP2964255B1 (en) | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
US10981961B2 (en) | 2013-03-11 | 2021-04-20 | University Of Florida Research Foundation, Incorporated | Delivery of card protein as therapy for occular inflammation |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
AU2013381687A1 (en) | 2013-03-12 | 2015-09-24 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
EP2968391A1 (en) * | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014165093A2 (en) | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014159239A2 (en) | 2013-03-14 | 2014-10-02 | Novartis Ag | Antibodies against notch 3 |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
TWI788044B (zh) | 2013-03-15 | 2022-12-21 | 美商百歐維拉提夫治療公司 | 因子ix多肽調配物 |
EP3473272A1 (en) | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
JP6464145B2 (ja) * | 2013-04-05 | 2019-02-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物製剤 |
DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
US9562101B2 (en) | 2013-06-21 | 2017-02-07 | Novartis Ag | Lectin-like oxidized LDL receptor 1 antibodies and methods of use |
AR096601A1 (es) | 2013-06-21 | 2016-01-20 | Novartis Ag | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso |
EA201592022A1 (ru) | 2013-06-28 | 2016-05-31 | Байоджен Ма Инк. | Расщепляемый тромбином линкер, содержащий xten, и его применение |
CN105339010A (zh) | 2013-06-28 | 2016-02-17 | 德国杰特贝林生物制品有限公司 | 使用因子xii抑制剂和c1-抑制剂的联合疗法 |
CN104342420B (zh) * | 2013-07-30 | 2017-09-15 | 惠觅宙 | 一种重组长效人透明质酸酶、其编码基因、生产方法及应用 |
EP4108254A1 (en) | 2013-08-14 | 2022-12-28 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
US9393177B2 (en) | 2013-08-20 | 2016-07-19 | Anutra Medical, Inc. | Cassette assembly for syringe fill system |
JP2016538318A (ja) | 2013-08-28 | 2016-12-08 | ステムセントリックス, インコーポレイテッド | 新規sez6モジュレーターおよび使用方法 |
CN105848671B (zh) | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
WO2015048330A2 (en) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | On-column viral inactivation methods |
CN103468662A (zh) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用 |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052131B1 (en) | 2013-10-01 | 2018-12-05 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
WO2015057403A2 (en) * | 2013-10-17 | 2015-04-23 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of inflammatory bowel disease |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
SI3063275T1 (sl) | 2013-10-31 | 2020-02-28 | Resolve Therapeutics, Llc | Terapevtske fuzije nukleaza-albumin in postopki |
CN105992770B (zh) * | 2013-11-01 | 2021-06-25 | 奥斯陆大学 | 白蛋白的变体及其用途 |
WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
CN114736305B (zh) | 2014-01-10 | 2023-05-05 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
JP6744227B2 (ja) | 2014-02-21 | 2020-08-19 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) | 糖標的化治療剤 |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
EP4050020A1 (en) | 2014-03-11 | 2022-08-31 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
US20170107294A1 (en) * | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
WO2015160618A1 (en) | 2014-04-16 | 2015-10-22 | Bayer Cropscience Lp | Compositions comprising ningnanmycin and a biological control agent |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
US20150316566A1 (en) | 2014-05-02 | 2015-11-05 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
CN105198999A (zh) * | 2014-05-27 | 2015-12-30 | 上海生物制品研究所有限责任公司 | 一种融合蛋白、其制备方法及其应用 |
USD763433S1 (en) | 2014-06-06 | 2016-08-09 | Anutra Medical, Inc. | Delivery system cassette |
USD774182S1 (en) | 2014-06-06 | 2016-12-13 | Anutra Medical, Inc. | Anesthetic delivery device |
USD750768S1 (en) | 2014-06-06 | 2016-03-01 | Anutra Medical, Inc. | Fluid administration syringe |
US10941182B2 (en) | 2014-06-10 | 2021-03-09 | Amgen Inc. | Apelin polypeptides |
CN106456778A (zh) | 2014-06-18 | 2017-02-22 | 德国杰特贝林生物制品有限公司 | 在神经创伤性病患中使用因子xii抑制剂进行治疗 |
WO2015198199A1 (en) | 2014-06-23 | 2015-12-30 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof. |
CN106459222A (zh) | 2014-06-24 | 2017-02-22 | 诺和诺德股份有限公司 | Mic‑1融合蛋白及其用途 |
WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
CN106573966B (zh) | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
US9988443B2 (en) | 2014-08-07 | 2018-06-05 | Novartis Ag | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use |
NZ728425A (en) | 2014-08-07 | 2022-05-27 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
AU2015305299B2 (en) * | 2014-08-22 | 2018-11-01 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
EP3209130B1 (en) | 2014-09-17 | 2023-03-01 | BASF Corporation | Compositions comprising recombinant bacillus cells and another biological control agent |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
AP2017009826A0 (en) | 2014-09-26 | 2017-03-31 | Bayer Pharma AG | Stabilized adrenomedullin derivatives and use thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
PL3207130T3 (pl) | 2014-10-14 | 2020-02-28 | Halozyme, Inc. | Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
US20160130324A1 (en) * | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
TWI669129B (zh) * | 2014-12-23 | 2019-08-21 | 德商梅茲製藥有限兩合公司 | 預填充式玻璃容器及其套組與使用 |
EP3277725B1 (en) * | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
JP2016204292A (ja) * | 2015-04-21 | 2016-12-08 | 国立大学法人 熊本大学 | Bmp7変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤 |
PT3288965T (pt) * | 2015-04-29 | 2019-10-15 | Mediolanum Farm S P A | Um recetor de interleucina-10 quimérico solúvel e sua utilização terapêutica |
WO2016195723A1 (en) * | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
ES2671844B1 (es) * | 2015-06-11 | 2019-03-22 | Attwill Medical Solutions Inc | Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina. |
JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
CN107921096A (zh) * | 2015-07-30 | 2018-04-17 | 恩多技术公司 | 用于胰腺癌或结肠癌治疗的集落刺激因子 |
RU2752530C2 (ru) | 2015-08-03 | 2021-07-29 | Новартис Аг | Способы лечения расстройств, связанных с fgf21 |
CN108472337B (zh) | 2015-08-03 | 2022-11-25 | 比奥贝拉蒂治疗公司 | 因子ix融合蛋白以及其制备和使用方法 |
WO2017024198A1 (en) * | 2015-08-06 | 2017-02-09 | The Trustees Of The University Of Pennsylvania | Glp-1 and use thereof in compositions for treating metabolic diseases |
AU2016308504A1 (en) | 2015-08-20 | 2018-01-18 | Albumedix Ltd. | Albumin variants and conjugates |
CN114591445B (zh) | 2015-09-08 | 2024-04-23 | Jcr制药股份有限公司 | 新型人血清白蛋白突变体 |
CN108350070B (zh) | 2015-09-09 | 2022-01-28 | 诺华股份有限公司 | 胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法 |
TN2018000076A1 (en) | 2015-09-09 | 2019-07-08 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules |
JP7299021B2 (ja) | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン/受容体ペア |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
TWI734719B (zh) | 2015-12-04 | 2021-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 在腫瘤細胞中拮抗wnt信號傳遞之雙抗體結合部位(biparatopic)多肽 |
AU2016366557B2 (en) | 2015-12-11 | 2024-01-25 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
WO2017103895A1 (en) | 2015-12-18 | 2017-06-22 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法 |
WO2017122130A1 (en) | 2016-01-11 | 2017-07-20 | Novartis Ag | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
WO2017125897A1 (en) | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
HRP20221089T1 (hr) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | Optimizirani geni faktora viii |
WO2017159540A1 (ja) | 2016-03-14 | 2017-09-21 | Jcrファーマ株式会社 | 血清アルブミン-20k成長ホルモン融合タンパク質 |
WO2017161414A1 (en) | 2016-03-22 | 2017-09-28 | Bionomics Limited | Administration of an anti-lgr5 monoclonal antibody |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
CN109071629A (zh) | 2016-04-06 | 2018-12-21 | 杰特有限公司 | 治疗动脉粥样硬化的方法 |
US11312766B2 (en) | 2016-04-27 | 2022-04-26 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
LT3458478T (lt) | 2016-05-18 | 2021-02-10 | Boehringer Ingelheim International Gmbh | Antikūnai prieš pd-1 ir lag-3, skirti vėžio gydymui |
US11434269B2 (en) | 2016-06-15 | 2022-09-06 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6) |
EP3481416B1 (en) * | 2016-07-08 | 2020-09-09 | CSL Behring Lengnau AG | Subcutaneous administration of long-acting factor ix in humans |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
AU2017305856A1 (en) | 2016-08-05 | 2019-03-21 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
JP2019534240A (ja) | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | C1エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018082758A1 (en) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
AU2017360043A1 (en) * | 2016-11-18 | 2019-06-20 | Hospital Clinic De Barcelona | Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
KR20190091292A (ko) | 2016-12-02 | 2019-08-05 | 바이오버라티브 테라퓨틱스 인크. | 응고 인자에 대한 면역 내성 유도 방법 |
IL308416A (en) | 2016-12-02 | 2024-01-01 | Bioverativ Therapeutics Inc | Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
AU2017383537A1 (en) | 2016-12-23 | 2019-06-27 | Novartis Ag | Methods of treatment with anti-factor XI/XIa antibodies |
CN110352242A (zh) | 2016-12-23 | 2019-10-18 | 哈佛大学的校长及成员们 | Pcsk9的基因编辑 |
US11168147B2 (en) | 2016-12-23 | 2021-11-09 | Novartis Ag | Factor XI antibodies and methods of use |
US20190382462A1 (en) | 2017-01-13 | 2019-12-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
BR112019015569A2 (pt) | 2017-01-31 | 2020-03-17 | Bioverativ Therapeutics Inc. | Proteínas de fusão do fator ix e métodos para a sua produção e uso |
KR102572663B1 (ko) | 2017-02-08 | 2023-09-01 | 노파르티스 아게 | Fgf21 모방 항체 및 이의 용도 |
US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
MA50141A (fr) | 2017-04-20 | 2020-07-29 | Novo Nordisk As | Procédés de purification de protéines de fusion d'albumine |
TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
AU2018276409A1 (en) | 2017-05-31 | 2019-10-31 | Boehringer Ingelheim International Gmbh | Polypeptides antagonizing Wnt signaling in tumor cells |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
KR102597725B1 (ko) | 2017-06-29 | 2023-11-06 | 체에스엘 베링 렝나우 아게 | 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법 |
EP3661562A1 (en) | 2017-08-04 | 2020-06-10 | Amgen Inc. | Method of conjugation of cys-mabs |
SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
WO2019036605A2 (en) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF |
CA3075686A1 (en) | 2017-09-15 | 2019-03-21 | Cedars-Sinai Medical Center | Methods for improving organ function in organ transplant patients |
US11466073B2 (en) | 2017-10-18 | 2022-10-11 | Csl Limited | Human serum albumin variants and uses thereof |
US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
BR112020011240A2 (pt) | 2017-12-15 | 2020-11-24 | Csl Limited | uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica |
WO2019129054A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
JP7369127B2 (ja) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー,リミテッド | Tigitに対する単一ドメイン抗体及びその変異体 |
US11246908B2 (en) * | 2018-01-10 | 2022-02-15 | The Johns Hopkins University | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
BR112020015228A2 (pt) | 2018-02-01 | 2020-12-29 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais que expressam fator viii |
ES2953362T3 (es) * | 2018-03-13 | 2023-11-10 | Sepsia Therapeutics S L | Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados |
WO2019173911A1 (en) | 2018-03-13 | 2019-09-19 | Zymeworks Inc. | Anti-her2 biparatopic antibody-drug conjugates and methods of use |
AU2019244091B2 (en) | 2018-03-28 | 2023-12-07 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
AU2019241350A1 (en) | 2018-03-30 | 2020-07-30 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
KR102119197B1 (ko) * | 2018-04-23 | 2020-06-05 | 주식회사 엘베이스 | 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물 |
EP3794024B1 (en) | 2018-05-14 | 2023-05-10 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
BR112020023167A2 (pt) | 2018-05-14 | 2021-02-09 | Werewolf Therapeutics, Inc. | polipeptídeos de citocina ativáveis e métodos de uso destes |
JP2021523878A (ja) | 2018-05-18 | 2021-09-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 血友病aを処置する方法 |
EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
EP3817720A2 (en) | 2018-07-03 | 2021-05-12 | Bristol-Myers Squibb Company | Fgf21 formulations |
JP2021533753A (ja) | 2018-08-09 | 2021-12-09 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
AU2019331024A1 (en) | 2018-08-31 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies |
JP2022500427A (ja) * | 2018-09-17 | 2022-01-04 | 国立大学法人京都大学 | 肝傷害又は肝不全の処置のための抗c5剤の投与 |
JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
KR20210111245A (ko) * | 2018-10-29 | 2021-09-10 | 스핀 테라퓨틱스, 엘엘씨 | 알파-1-항트립신 장애들을 위한 조성물들 및 방법들 |
GB201818477D0 (en) | 2018-11-13 | 2018-12-26 | Emstopa Ltd | Tissue plasminogen activator antibodies and method of use thereof |
CN113396158A (zh) | 2018-11-26 | 2021-09-14 | 诺华股份有限公司 | Lpl-gpihbp1融合多肽 |
CA3121786A1 (en) | 2018-12-06 | 2020-06-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor ix |
CN114144433A (zh) | 2019-03-22 | 2022-03-04 | 反射制药有限公司 | 用于目标蛋白的多价d-肽化合物 |
EP3941580A1 (en) | 2019-03-22 | 2022-01-26 | Reflexion Pharmaceuticals, Inc. | D-peptidic compounds for vegf |
WO2020198731A2 (en) | 2019-03-28 | 2020-10-01 | Danisco Us Inc | Engineered antibodies |
KR20220004083A (ko) | 2019-04-11 | 2022-01-11 | 앤지온 바이오메디카 코포레이션 | (e)-3-[2-(2-티에닐)비닐]-1h-피라졸의 고체 형태 |
CN114450022A (zh) | 2019-05-14 | 2022-05-06 | 狼人治疗公司 | 分离部分及其使用方法 |
MX2021014164A (es) | 2019-05-21 | 2022-01-04 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas. |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
WO2020242989A1 (en) | 2019-05-24 | 2020-12-03 | Sanofi | Methods for treating systemic sclerosis |
CN114174326A (zh) | 2019-06-18 | 2022-03-11 | 拜耳公司 | 长期稳定的肾上腺髓质素类似物及其用途 |
JP2022547051A (ja) | 2019-09-06 | 2022-11-10 | ノバルティス アーゲー | 治療用融合タンパク質 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
EP4038182A1 (en) | 2019-09-30 | 2022-08-10 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
US20240132566A1 (en) | 2019-10-16 | 2024-04-25 | Jcr Pharmaceuticals Co., Ltd. | Method for producing fusion protein of serum albumin and growth hormone |
EP4059512A4 (en) | 2019-10-30 | 2023-12-06 | JCR Pharmaceuticals Co., Ltd. | AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING SERUM ALBUMIN FUSION PROTEIN AND GROWTH HORMONE |
EP4069200A1 (en) | 2019-12-04 | 2022-10-12 | Albumedix Ltd | Methods and compositions produced thereby |
AU2020401371A1 (en) | 2019-12-13 | 2022-07-21 | Synthekine, Inc. | IL-2 orthologs and methods of use |
US20210181200A1 (en) * | 2019-12-17 | 2021-06-17 | Women's College Hospital | Ovarian cancer biomarker and methods of using same |
WO2021202473A2 (en) | 2020-03-30 | 2021-10-07 | Danisco Us Inc | Engineered antibodies |
BR112022021447A2 (pt) | 2020-05-19 | 2022-12-13 | Boehringer Ingelheim Int | Moléculas de ligação para o tratamento de câncer |
EP4232474A1 (en) | 2020-10-21 | 2023-08-30 | Boehringer Ingelheim International GmbH | Bispecific anti-vegf and anti-trkb binding molecules for the treatment of eye diseases |
IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | CD19 binding molecules and their uses |
CN114478800B (zh) * | 2021-02-05 | 2022-10-11 | 华南理工大学 | 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用 |
AU2022224636A1 (en) | 2021-02-19 | 2023-09-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies that neutralize sars-cov-2 |
TW202317625A (zh) | 2021-06-17 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 新穎三特異性結合分子 |
CN114133458B (zh) * | 2021-12-08 | 2023-11-14 | 福州大学 | 一种在人血清白蛋白内部融合多肽的方法 |
WO2023209568A1 (en) | 2022-04-26 | 2023-11-02 | Novartis Ag | Multispecific antibodies targeting il-13 and il-18 |
US20240052065A1 (en) | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Family Cites Families (517)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625041A (en) * | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4440859A (en) * | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
US4264731A (en) * | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
US4363877B1 (en) | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
US4407948A (en) | 1977-09-23 | 1983-10-04 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
US4283489A (en) | 1977-09-23 | 1981-08-11 | The Regents Of The University Of California | Purification of nucleotide sequences suitable for expression in bacteria |
US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4652525A (en) * | 1978-04-19 | 1987-03-24 | The Regents Of The University Of California | Recombinant bacterial plasmids containing the coding sequences of insulin genes |
US4447538A (en) * | 1978-04-19 | 1984-05-08 | Regents Of The University Of California | Microorganism containing gene for human chorionic somatomammotropin |
US5514567A (en) * | 1979-01-30 | 1996-05-07 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
US5326859A (en) | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
US4342832A (en) | 1979-07-05 | 1982-08-03 | Genentech, Inc. | Method of constructing a replicable cloning vehicle having quasi-synthetic genes |
AU538665B2 (en) | 1979-10-30 | 1984-08-23 | Juridical Foundation, Japanese Foundation For Cancer Research | Human interferon dna |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
CA1341567C (en) | 1980-01-08 | 2008-02-19 | Charles Weissmann | Dna sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides |
ES500966A0 (es) | 1980-04-03 | 1982-12-16 | Biogen Nv | Un metodo de producir un polipeptido que muestra una actividad immunologica obiologica de interferon de fibroblasto hu- mano. |
DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
US6610830B1 (en) | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
IL63916A0 (en) | 1980-09-25 | 1981-12-31 | Genentech Inc | Microbial production of human fibroblast interferon |
DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
US4456748A (en) | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
JPS57149228A (en) | 1981-03-11 | 1982-09-14 | Ajinomoto Co Inc | Novel erythropoietin and its preparation |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4792602A (en) | 1981-06-19 | 1988-12-20 | Cornell Research Foundation, Inc. | Adaptors, and synthesis and cloning of proinsulin genes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
IL66614A (en) | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
EP0079739A3 (en) | 1981-11-12 | 1984-08-08 | The Upjohn Company | Albumin-based nucleotides, their replication and use, and plasmids for use therein |
EP0091527A3 (en) | 1981-12-14 | 1984-07-25 | The President And Fellows Of Harvard College | Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
IT1167610B (it) | 1982-01-19 | 1987-05-13 | Cetus Corp | Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4450103A (en) * | 1982-03-01 | 1984-05-22 | Cetus Corporation | Process for recovering human IFN-β from a transformed microorganism |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4670393A (en) | 1982-03-22 | 1987-06-02 | Genentech, Inc. | DNA vectors encoding a novel human growth hormone-variant protein |
US4925919A (en) * | 1984-04-25 | 1990-05-15 | Roland Mertelsmann | Purified interleukin 2 |
US4778879A (en) | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
US4499188A (en) * | 1982-05-05 | 1985-02-12 | Cetus Corporation | Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4992271A (en) | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4462940A (en) * | 1982-09-23 | 1984-07-31 | Cetus Corporation | Process for the recovery of human β-interferon-like polypeptides |
IE56026B1 (en) | 1982-10-19 | 1991-03-27 | Cetus Corp | Cysteine-depleted muteins of biologically active proteins |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4966843A (en) * | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
DE3382547D1 (de) | 1983-01-12 | 1992-05-27 | Chiron Corp | Sekretorische expression in eukaryoten. |
US4840934A (en) * | 1983-01-25 | 1989-06-20 | Eleanor Roosevelt Institute For Cancer Research, Inc. | Therapeutic method using T cell growth factor |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5015575A (en) * | 1983-04-07 | 1991-05-14 | Chiron Corporation | Hybrid DNA synthesis of insulin |
US4914026A (en) * | 1983-04-07 | 1990-04-03 | Chiron Corporation | Alpha factor leader sequence directed secretion of insulin |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
JPS60501140A (ja) | 1983-04-22 | 1985-07-25 | アムジエン | 酵母による外因性ポリペプチドの分泌 |
NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
US5010003A (en) * | 1983-04-25 | 1991-04-23 | Genentech, Inc. | Use of yeast homologous signals to secrete heterologous proteins |
CA1196863A (en) * | 1983-06-08 | 1985-11-19 | Mattheus F.A. Goosen | Slow release injectable insulin composition |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4576813A (en) | 1983-07-05 | 1986-03-18 | Monsanto Company | Heat recovery from concentrated sulfuric acid |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
JPS6087792A (ja) | 1983-09-23 | 1985-05-17 | ジェネックス・コーポレイション | 雑種制御領域 |
EP0142641B1 (de) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
US4518564A (en) * | 1983-10-03 | 1985-05-21 | Jeneric Industries, Inc. | Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
GB8334102D0 (en) | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
NZ210501A (en) * | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
GB8334261D0 (en) | 1983-12-22 | 1984-02-01 | Bass Plc | Fermentation processes |
JPS60136596A (ja) | 1983-12-26 | 1985-07-20 | Suntory Ltd | ペプチド及びこれを有効成分とする利尿剤 |
US4908434A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Process for preparing purified interleukin-2 |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
FR2564106B1 (fr) * | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
DK58285D0 (da) * | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
EP0172619A1 (en) | 1984-06-20 | 1986-02-26 | Takeda Chemical Industries, Ltd. | Novel transformant and use thereof |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US5908763A (en) | 1984-07-06 | 1999-06-01 | Novartis Corporation | DNA encoding GM-CSF and a method of producing GM-CSF protein |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
US4716217A (en) | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
US4734491A (en) | 1984-08-31 | 1988-03-29 | University Patents, Inc. | DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
GB8504099D0 (en) * | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
FR2579224B1 (fr) * | 1985-03-25 | 1987-05-22 | Genetica | Procede de preparation microbiologique de la serum-albumine humaine |
ATE63757T1 (de) | 1985-03-28 | 1991-06-15 | Chiron Corp | Expression durch verwendung von fusionsgenen fuer proteinproduktion. |
US4751180A (en) * | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
GB8510219D0 (en) | 1985-04-22 | 1985-05-30 | Bass Plc | Isolation of fermentation products |
JPS6229985A (ja) | 1985-06-17 | 1987-02-07 | ジエネツクス・コ−ポレ−シヨン | クロ−ン化プレプロ−ヒト血清アルブミン遺伝子およびヒト血清アルブミン遺伝子、それらの遺伝子を含むプラスミド、プラスミドにより形質転換された微生物、およびその微生物を用いたプレプロ−ヒト血清アルブミン遺伝子の製造方法 |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
JPS6296086A (ja) | 1985-10-21 | 1987-05-02 | Agency Of Ind Science & Technol | 複合プラスミド |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
US5576195A (en) | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
CA1295566C (en) | 1987-07-21 | 1992-02-11 | Robert T. Garvin | Characterization and structure of genes for protease a and protease b from streptomyces griseus |
US5641663A (en) * | 1985-11-06 | 1997-06-24 | Cangene Corporation | Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
FR2594846B1 (fr) * | 1986-02-21 | 1989-10-20 | Genetica | Procede de preparation de la serum albumine humaine mature |
EP0237019A3 (en) | 1986-03-14 | 1988-03-09 | Toray Industries, Inc. | Interferon conjugate and production thereof using recombinant gene |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IT1203758B (it) | 1986-03-27 | 1989-02-23 | Univ Roma | Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori |
DK179286D0 (da) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
US4765980A (en) * | 1986-04-28 | 1988-08-23 | International Minerals & Chemical Corp. | Stabilized porcine growth hormone |
US4859609A (en) | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
US5028422A (en) * | 1986-05-27 | 1991-07-02 | Schering Corporation | Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon |
IT1204400B (it) * | 1986-06-20 | 1989-03-01 | Sclavo Spa | Composizioni farmaceutiche contenente una calcitonina |
GB8615701D0 (en) | 1986-06-27 | 1986-08-06 | Delta Biotechnology Ltd | Stable gene integration vector |
IT1196484B (it) | 1986-07-11 | 1988-11-16 | Sclavo Spa | Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US5002764A (en) * | 1986-08-12 | 1991-03-26 | Schering Corporation | Treatment of actinic keratoses with alpha2 interferon |
GB8620926D0 (en) | 1986-08-29 | 1986-10-08 | Delta Biotechnology Ltd | Yeast promoter |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
US5508031A (en) * | 1986-11-21 | 1996-04-16 | Cetus Oncology Corporation | Method for treating biological damage using a free-radial scavenger and interleukin-2 |
JPH01502669A (ja) | 1987-03-13 | 1989-09-14 | アムジエン・インコーポレーテツド | 精製された血小板由来の成長因子及びその精製方法 |
US4835260A (en) * | 1987-03-20 | 1989-05-30 | Genetics Institute, Inc. | Erythropoietin composition |
HU213344B (en) * | 1987-04-09 | 1997-05-28 | Delta Biotechnology Ltd | Process for producing of stable dezintegrating plasmid-vectors |
DE3855504T2 (de) | 1987-04-22 | 1997-01-23 | Chiron Corp | Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
IL87258A (en) | 1987-07-28 | 1994-02-27 | Gist Brocades Nv | SECYMOREVYULK surrogate cells and their use for the expression of polypeptides |
JP2627899B2 (ja) | 1987-08-19 | 1997-07-09 | 株式会社 ビタミン研究所 | 遺伝子封入リポソームの製法 |
SE459586B (sv) | 1987-09-14 | 1989-07-17 | Mta Szegedi Biolog Koezponti | Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning |
NZ226414A (en) | 1987-10-02 | 1992-07-28 | Genentech Inc | Cd4 peptide adhesion variants and their preparation and use |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
GB8725529D0 (en) * | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
JPH0811074B2 (ja) | 1987-10-30 | 1996-02-07 | 財団法人化学及血清療法研究所 | プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法 |
JP2791418B2 (ja) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えdna、形質転換体 |
PT89484B (pt) | 1988-01-22 | 1994-03-31 | Gen Hospital Corp | Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao |
JPH01240191A (ja) * | 1988-02-16 | 1989-09-25 | Green Cross Corp:The | 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現 |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
US4999339A (en) * | 1988-03-28 | 1991-03-12 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US5066489A (en) | 1988-03-28 | 1991-11-19 | Cetus Corporation | Combination therapy of IL-2 and DTIC for the treatment of melanoma |
US5096707A (en) * | 1988-04-15 | 1992-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5061488A (en) | 1988-04-15 | 1991-10-29 | The United States Of America As Represented Department Of Health & Human Services | Flavone-8-acetic acid and interleukin-2 for cancer therapy |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
IL89992A0 (en) | 1988-04-25 | 1989-12-15 | Phillips Petroleum Co | Expression of human serum albumin in methylotrophic yeasts |
US5126129A (en) * | 1988-05-23 | 1992-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Cancer therapy using interleukin-2 and flavone compounds |
CA1341373C (en) | 1988-06-24 | 2002-07-02 | Roberta C. Cheng | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
AU633020B2 (en) | 1988-07-23 | 1993-01-21 | Novozymes Delta Limited | New secretory leader sequences |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
FR2635115B1 (fr) | 1988-08-05 | 1992-04-03 | Rhone Poulenc Sante | Procede de preparation de la serum albumine humaine a partir d'une levure |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
EP1892296A1 (en) | 1988-09-02 | 2008-02-27 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
US5260202A (en) | 1988-09-07 | 1993-11-09 | Delta Biotechnology Limited | Fermentation method |
JPH02227079A (ja) | 1988-10-06 | 1990-09-10 | Tonen Corp | ヒト血清アルブミン断片 |
US5298243A (en) | 1988-10-20 | 1994-03-29 | Denki Kagaku Kogyo Kabushiki Kaisha | Colony stimulating factor-gelatin conjugate |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5759802A (en) | 1988-10-26 | 1998-06-02 | Tonen Corporation | Production of human serum alubumin A |
JPH02117384A (ja) | 1988-10-26 | 1990-05-01 | Tonen Corp | 酵母宿主によるヒト血清アルブミンaの製造 |
US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5256410A (en) | 1988-12-01 | 1993-10-26 | Schering Corporation | Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
DK105489D0 (da) * | 1989-03-03 | 1989-03-03 | Novo Nordisk As | Polypeptid |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
DK0465529T3 (da) | 1989-03-21 | 1998-10-05 | Vical Inc | Ekspression af exogene polynukleotidsekvenser i et hvirveldyr |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
DE59000270D1 (de) * | 1989-04-11 | 1992-10-01 | Boehringer Ingelheim Int | Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen. |
EP0395918A3 (en) | 1989-04-13 | 1991-10-23 | Vascular Laboratory, Inc. | Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
US5766883A (en) * | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
EP0399816B1 (en) | 1989-05-24 | 1995-12-20 | Merck & Co. Inc. | Purification and characterization of a glioma-derived growth factor |
US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
ATE125869T1 (de) * | 1989-06-09 | 1995-08-15 | Gropep Pty Ltd | Wachstumshormonfusionsproteine. |
JPH0327320A (ja) | 1989-06-26 | 1991-02-05 | Ajinomoto Co Inc | ヒトb細胞分化因子医薬組成物 |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
CU22222A1 (es) | 1989-08-03 | 1995-01-31 | Cigb | Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes |
GB8927480D0 (en) | 1989-12-05 | 1990-02-07 | Delta Biotechnology Ltd | Mutant fungal strain detection and new promoter |
US5073627A (en) * | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6063373A (en) * | 1989-09-19 | 2000-05-16 | Maxim Pharmaceuticals, Inc. | Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor |
CA1340994C (en) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
FR2653020B1 (fr) | 1989-10-17 | 1993-03-26 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies. |
GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
WO1991006309A1 (en) | 1989-11-03 | 1991-05-16 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5173408A (en) | 1989-11-13 | 1992-12-22 | Lange Louis George Iii | Mammalian pancreatic cholesterol esterase |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JPH03201987A (ja) | 1989-12-29 | 1991-09-03 | Tonen Corp | ヒト血清アルブミン断片 |
US5116944A (en) * | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
ES2086521T3 (es) * | 1990-01-25 | 1996-07-01 | Univ Washington | Proteina hibrida laci-factor x. |
JPH04211375A (ja) | 1990-02-05 | 1992-08-03 | Ajinomoto Co Inc | 合成遺伝子及びそれを用いたヒト血清アルブミンの製造法 |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
US5208018A (en) * | 1990-03-19 | 1993-05-04 | Brigham And Women's Hospital | Treatment of cachexia with interleukin 2 |
FR2660863B1 (fr) * | 1990-04-17 | 1994-01-21 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre. |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992001055A1 (de) | 1990-07-10 | 1992-01-23 | Boehringer Ingelheim International Gmbh | O-glycosyliertes ifn-alpha |
US5225341A (en) | 1990-07-19 | 1993-07-06 | The Regents Of The University Of California | Biologically safe plant transformation system using a ds transposon |
US5202239A (en) * | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
US5071872A (en) | 1990-08-14 | 1991-12-10 | The Ohio State University Research Foundation | Method for improving interleukin-2 activity using aci-reductone compounds |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5391183A (en) * | 1990-09-21 | 1995-02-21 | Datascope Investment Corp | Device and method sealing puncture wounds |
IT1242149B (it) | 1990-09-27 | 1994-02-16 | Consiglio Nazionale Ricerche | Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
ATE175118T1 (de) | 1990-10-05 | 1999-01-15 | Medarex Inc | Gezielte immunostimulierung mit bispezifischen stoffen |
JPH07108232B2 (ja) | 1990-10-09 | 1995-11-22 | エム・ディ・リサーチ株式会社 | ペプチド又は蛋白質の製造方法 |
DE69128253T2 (de) | 1990-10-29 | 1998-06-18 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
FR2668368B1 (fr) | 1990-10-30 | 1995-03-10 | Roussel Uclaf | Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales. |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
JPH0638771A (ja) | 1990-10-31 | 1994-02-15 | Tonen Corp | ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法 |
US5353535A (en) | 1990-11-05 | 1994-10-11 | Plumly George W | Floor type advertising apparatus |
DE69133340D1 (de) | 1990-11-29 | 2003-12-18 | Agronomique Inst Nat Rech | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5272080A (en) * | 1991-02-19 | 1993-12-21 | Pharmavene, Inc. | Production of butyrylcholinesterase |
US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5272070A (en) * | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
EP0503583A1 (en) | 1991-03-12 | 1992-09-16 | Takeda Chemical Industries, Ltd. | Composition for sustained release of erythropoietin |
US5811396A (en) | 1991-03-14 | 1998-09-22 | The United States Of America As Represented By The Department Of Health And Human Services | TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor |
DE69229454T2 (de) | 1991-03-28 | 2000-01-05 | Merck & Co Inc | Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors |
US5374617A (en) | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
EP0509841A3 (en) | 1991-04-18 | 1993-08-18 | Tonen Corporation | Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
US5330901A (en) | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
FR2676070B1 (fr) | 1991-04-30 | 1994-09-30 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisation. |
US5646012A (en) * | 1991-04-30 | 1997-07-08 | Rhone-Poulenc Rorer S.A. | Yeast promoter and use thereof |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5304473A (en) * | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
FR2677996B1 (fr) | 1991-06-21 | 1993-08-27 | Rhone Poulenc Rorer Sa | Vecteurs de clonage et/ou d'expression preparation et utilisation. |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5223408A (en) * | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
JPH05292972A (ja) | 1991-07-29 | 1993-11-09 | Tonen Corp | 改良された酵母発現系 |
US5723719A (en) | 1991-08-08 | 1998-03-03 | Health Research Inc. | Transgenic mouse as model for diseases involving dopaminergic dysfunction |
DE4126968A1 (de) | 1991-08-14 | 1993-02-18 | Detlev Prof Dr Med Ganten | Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US6270989B1 (en) | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
NZ245015A (en) * | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
DE69226197T2 (de) * | 1991-11-08 | 1999-02-11 | Somatogen Inc | Hämoglobine als arzneimittelabgabesystem |
US5786883A (en) * | 1991-11-12 | 1998-07-28 | Pilkington Barnes Hind, Inc. | Annular mask contact lenses |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US6348327B1 (en) * | 1991-12-06 | 2002-02-19 | Genentech, Inc. | Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells |
US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
ES2204899T3 (es) | 1992-01-07 | 2004-05-01 | Elan Pharmaceuticals, Inc. | Modelos de animales transgenicos para la enfermedad de alzheimer. |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
FR2686900B1 (fr) * | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
US5230886A (en) | 1992-03-18 | 1993-07-27 | Trustees Of Boston University | Tumor cell suppression |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5460954A (en) | 1992-04-01 | 1995-10-24 | Cheil Foods & Chemicals, Inc. | Production of human proinsulin using a novel vector system |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
AU658072B2 (en) | 1992-06-09 | 1995-03-30 | Hoppe Ag | Latch and lockset system |
US5686268A (en) * | 1992-06-19 | 1997-11-11 | Pfizer Inc. | Fused proteins |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
JP3269504B2 (ja) | 1992-07-08 | 2002-03-25 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの製造方法 |
FR2694294B1 (fr) * | 1992-07-30 | 1994-09-09 | Rhone Poulenc Rorer Sa | Promoteur de levure et son utilisateur. |
AU686567C (en) | 1992-07-31 | 2002-08-08 | Genentech Inc. | Human growth hormone aqueous formulation |
US5602307A (en) | 1992-08-12 | 1997-02-11 | Baylor College Of Medicine | Non-human animal having predefined allele of a cellular adhesion gene |
DE4226971C2 (de) * | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
US5731490A (en) | 1992-09-29 | 1998-03-24 | The Ontario Cancer Institute | Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1) |
AU5171293A (en) * | 1992-10-14 | 1994-05-09 | Regents Of The University Of Colorado, The | Ion-pairing of drugs for improved efficacy and delivery |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
US6221958B1 (en) * | 1993-01-06 | 2001-04-24 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5489743A (en) | 1993-01-19 | 1996-02-06 | Amgen Inc. | Transgenic animal models for thrombocytopenia |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
FR2701953B1 (fr) | 1993-02-22 | 1995-05-24 | Centre Nat Rech Scient | Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant. |
US5441734A (en) | 1993-02-25 | 1995-08-15 | Schering Corporation | Metal-interferon-alpha crystals |
US5780021A (en) | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
HU219682B (hu) * | 1993-05-21 | 2001-06-28 | Novo Nordisk A/S. | Módosított VII faktor |
WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
DK82893D0 (da) * | 1993-07-08 | 1993-07-08 | Novo Nordisk As | Peptid |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
US5521086A (en) * | 1993-09-16 | 1996-05-28 | Cephalon, Inc. | Secretion sequence for the production of a heterologous protein in yeast |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5459031A (en) | 1993-11-05 | 1995-10-17 | Amgen Inc. | Methods for controlling sialic acid derivatives in recombinant glycoproteins |
EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
DK0744958T3 (da) | 1994-01-31 | 2003-10-20 | Univ Boston | Polyklonale antistofbiblioteker |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5932780A (en) | 1994-02-28 | 1999-08-03 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Transgenic non-human animal assay system for anti-cholinesterase substances |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
US5629286A (en) * | 1994-03-31 | 1997-05-13 | Brewitt; Barbara | Homeopathic dilutions of growth factors |
US5646113A (en) | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
FR2719593B1 (fr) | 1994-05-06 | 1996-05-31 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant. |
GB9411356D0 (en) | 1994-06-07 | 1994-07-27 | Delta Biotechnology Ltd | Yeast strains |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
US5639642A (en) * | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
US5623054A (en) | 1994-06-23 | 1997-04-22 | The General Hospital Corporation | Crucifer AFT proteins and uses thereof |
JPH0851982A (ja) | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | ヒト血清アルブミンをコードする改変された遺伝子 |
US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
US6071923A (en) * | 1994-09-16 | 2000-06-06 | Bar-Ilan University | Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
EP0792278B1 (en) | 1994-11-07 | 2007-06-13 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
FR2726471B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
FR2726576B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante |
AT403167B (de) | 1994-11-14 | 1997-11-25 | Immuno Ag | Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems |
US5695750A (en) | 1994-11-25 | 1997-12-09 | The United States Of America As Represented By The Secretary Of The Army | Compositions for use to deactivate organophosphates |
JPH11501506A (ja) * | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | キメラ型サイトカインおよびその利用 |
US5652224A (en) | 1995-02-24 | 1997-07-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
US5837281A (en) * | 1995-03-17 | 1998-11-17 | Takeda Chemical Industries, Ltd. | Stabilized interface for iontophoresis |
TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
WO1996034095A1 (en) | 1995-04-27 | 1996-10-31 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5480640A (en) | 1995-05-02 | 1996-01-02 | Schering Corporation | Alpha interferon for treating prostate cancer |
MX9708537A (es) | 1995-05-05 | 1998-02-28 | Human Genome Sciences Inc | Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas. |
US5728915A (en) | 1995-05-08 | 1998-03-17 | Children's Hospital, Inc. | Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter |
US5705151A (en) | 1995-05-18 | 1998-01-06 | National Jewish Center For Immunology & Respiratory Medicine | Gene therapy for T cell regulation |
US6387365B1 (en) | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US6001625A (en) | 1995-05-19 | 1999-12-14 | The United States Of America As Represented By The Secretary Of The Army | Site-directed mutagenesis of esterases |
US5741815A (en) * | 1995-06-02 | 1998-04-21 | Lai; Ching-San | Methods for in vivo reduction of nitric oxide levels and compositions useful therefor |
US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
CA2329474C (en) | 1995-11-02 | 2002-02-26 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6087129A (en) * | 1996-01-19 | 2000-07-11 | Betagene, Inc. | Recombinant expression of proteins from secretory cell lines |
US6110707A (en) * | 1996-01-19 | 2000-08-29 | Board Of Regents, The University Of Texas System | Recombinant expression of proteins from secretory cell lines |
US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
US6150337A (en) | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
DE19639601A1 (de) | 1996-02-28 | 1997-09-04 | Bayer Ag | Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen |
US6045788A (en) * | 1996-02-28 | 2000-04-04 | Cornell Research Foundation, Inc. | Method of stimulation of immune response with low doses of IL-2 |
US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
JP3794748B2 (ja) * | 1996-03-04 | 2006-07-12 | 第一アスビオファーマ株式会社 | メタノール代謝系を有する微生物の培養法 |
WO1997033904A1 (en) | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
JP2000506865A (ja) | 1996-03-14 | 2000-06-06 | ジ イミューン リスポンス コーポレイション | インターフェロンをコードする遺伝子の標的を定めた送達 |
CA2248136A1 (en) * | 1996-03-21 | 1997-09-25 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor i, ii and iii |
EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
US6204022B1 (en) * | 1996-04-12 | 2001-03-20 | Pepgen Corporation And University Of Florida | Low-toxicity human interferon-alpha analogs |
EP1854481B1 (en) * | 1996-04-23 | 2014-07-16 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient |
ATE196844T1 (de) * | 1996-05-22 | 2000-10-15 | Protarga Inc | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten |
US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
EP0917566B1 (de) * | 1996-06-11 | 2004-09-22 | Roche Diagnostics GmbH | Rekombinante blutgerinnungsproteasen |
US6828426B1 (en) | 1996-07-15 | 2004-12-07 | Chugai Seiyaku Kabushiki Kaisha | VEGF-like factor |
DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
ES2316153T3 (es) | 1996-08-16 | 2009-04-01 | Human Genome Sciences, Inc. | Endoquina alfa humana. |
DK0956339T3 (da) | 1996-08-23 | 2006-01-30 | Licentia Oy | Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D) |
AU7364696A (en) * | 1996-09-18 | 1998-04-14 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
US5994112A (en) | 1996-10-09 | 1999-11-30 | Incyte Pharmaceuticals, Inc. | Human protein tyrosine kinase |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US5955508A (en) * | 1996-10-15 | 1999-09-21 | Loyola University Of Chicago | Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens |
AU4988697A (en) | 1996-10-24 | 1998-05-15 | Vion Pharmaceuticals, Inc. | Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents |
PT939804E (pt) | 1996-10-25 | 2005-11-30 | Human Genome Sciences Inc | Neutroquina alfa |
JPH10134761A (ja) | 1996-10-30 | 1998-05-22 | Ebara Corp | イオン注入装置及びイオン注入方法 |
US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
GB9623205D0 (en) * | 1996-11-07 | 1997-01-08 | Eurand Int | Novel pharmaceutical compositions |
ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
US5833994A (en) | 1997-01-08 | 1998-11-10 | Paracelsian, Inc. | Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection |
AU6238698A (en) | 1997-01-14 | 1998-08-03 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
JP2001527387A (ja) * | 1997-01-24 | 2001-12-25 | ノボ ノルディスク アクティーゼルスカブ | 合成リーダーペプチド配列 |
PT1012274E (pt) | 1997-01-28 | 2007-08-14 | Craig A Rosen | Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02) |
WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
GB2324529A (en) | 1997-02-21 | 1998-10-28 | Merck & Co Inc | A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases |
US7026447B2 (en) * | 1997-10-09 | 2006-04-11 | Human Genome Sciences, Inc. | 53 human secreted proteins |
US6030961A (en) * | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1998050347A1 (en) | 1997-05-05 | 1998-11-12 | The Regents Of The University Of California | Naphthols useful in antiviral methods |
JP2002511070A (ja) | 1997-05-30 | 2002-04-09 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | ヒト腫瘍壊死因子受容体tr10 |
US6071743A (en) | 1997-06-02 | 2000-06-06 | Subsidiary No. 3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
AU7830398A (en) | 1997-06-11 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr9 |
GB9713412D0 (en) | 1997-06-26 | 1997-08-27 | Delta Biotechnology Ltd | Improved protein expression strains |
US5858719A (en) | 1997-07-17 | 1999-01-12 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding human ATP binding-cassette transport protein and methods of use |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
EP1136075B1 (en) | 1997-09-21 | 2003-01-15 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
US6201072B1 (en) * | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
CA2305690A1 (en) * | 1997-10-09 | 1999-04-22 | Human Genome Sciences, Inc. | 53 human secreted proteins |
ATE384732T1 (de) | 1997-11-03 | 2008-02-15 | Human Genome Sciences Inc | Vegi, ein inhibitor der angiogenese und des tumorwachstums |
DE69822505T2 (de) * | 1997-12-08 | 2005-01-20 | Bristol-Myers Squibb Co. | Neue metformin-salze und verfahren |
ES2590912T3 (es) * | 1997-12-08 | 2016-11-24 | Merck Patent Gmbh | Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
DE19813802A1 (de) | 1998-03-27 | 1999-11-11 | Retro Tech Gmbh | Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen |
GB9806631D0 (en) | 1998-03-28 | 1998-05-27 | Safeglass Europ Limited | Safetyglass |
US6251868B1 (en) | 1998-04-30 | 2001-06-26 | Teijin Limited | Method for treating a human immunodeficiency virus infection |
MY129244A (en) | 1998-05-15 | 2007-03-30 | Schering Corp | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection. |
CN1119352C (zh) | 1998-05-15 | 2003-08-27 | 中国科学院上海生物化学研究所 | 人血清白蛋白在毕赤酵母中的表达与纯化 |
US5970300A (en) * | 1998-06-01 | 1999-10-19 | Xerox Corporation | Apparatus for applying scents to paper in a printer/copier |
EP1088084B1 (en) * | 1998-06-15 | 2006-09-13 | GTC Biotherapeutics, Inc. | Erythropoietin analog-human serum albumin fusion protein |
CN1105727C (zh) | 1998-06-17 | 2003-04-16 | 上海海济医药生物工程有限公司 | 重组人血清白蛋白的生产方法 |
AU4716299A (en) | 1998-06-24 | 2000-01-10 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
GB9817084D0 (en) | 1998-08-06 | 1998-10-07 | Wood Christopher B | A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders |
US6346543B1 (en) * | 1998-08-17 | 2002-02-12 | Aventis Pharma S.A. | Use of a taxoid to treat abnormal cell proliferation in the brain |
US6193997B1 (en) * | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
US7232889B2 (en) * | 1999-03-08 | 2007-06-19 | Genentech, Inc. | PRO300 antibodies |
US6348192B1 (en) * | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
MXPA01011845A (es) | 1999-05-19 | 2002-06-21 | Lexigen Pharm Corp | Expresion y exportacion de proteinas de interferon-alfa como proteinas de fusion fc. |
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
US20020048571A1 (en) * | 1999-07-19 | 2002-04-25 | Jeno Gyuris | Chimeric polypeptides of serum albumin and uses related thereto |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
WO2001029242A2 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
US6569832B1 (en) * | 1999-11-12 | 2003-05-27 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003530838A (ja) * | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP3967594B2 (ja) * | 2000-05-15 | 2007-08-29 | エフ.ホフマン−ラ ロシュ アーゲー | 新しい薬剤組成物 |
US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
JP2004528014A (ja) | 2000-12-07 | 2004-09-16 | イーライ・リリー・アンド・カンパニー | Glp−1融合タンパク質 |
US7070973B2 (en) | 2000-12-26 | 2006-07-04 | Board Of Regents Of The University Of Nebraska | Butyrylcholinesterase variants and methods of use |
US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2002097038A2 (en) | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
EP1423136A4 (en) | 2001-08-10 | 2007-07-25 | Epix Pharm Inc | POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES |
WO2003030821A2 (en) | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2516041T3 (es) | 2001-10-10 | 2014-10-30 | Ratiopharm Gmbh | Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH) |
CA2471363C (en) * | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080167238A1 (en) | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
WO2003054182A2 (en) | 2001-12-21 | 2003-07-03 | Nexia Biotechnologies, Inc. | Production of butyrylcholinesterases in transgenic mammals |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
CN1241946C (zh) * | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
US6913890B2 (en) * | 2002-12-18 | 2005-07-05 | Palo Alto Research Center Incorporated | Process for preparing albumin protein conjugated oligonucleotide probes |
EP1596888B1 (en) * | 2003-02-27 | 2012-01-11 | Baxter International Inc. | Method for the validatable inactivation of pathogens in a biological fluid by irradiation |
NZ548612A (en) * | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
US20060051859A1 (en) | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
US7436410B2 (en) * | 2005-04-01 | 2008-10-14 | Seiko Epson Corporation | System and method for programming a controller |
MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
US7438904B1 (en) | 2005-10-04 | 2008-10-21 | University Of Kentucky Research Foundation | High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same |
US8008257B2 (en) | 2005-10-20 | 2011-08-30 | University Of Ottawa Heart Institute | ANF fusion proteins |
EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
SI2717898T1 (sl) * | 2011-06-10 | 2019-07-31 | Bioverativ Therapeutics Inc. | Spojine prokoagulantov in metode za njihovo uporabo |
-
2001
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/ja active Pending
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/ja active Pending
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en active Application Filing
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/es not_active Expired - Lifetime
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/ja active Pending
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Application Discontinuation
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/ja active Pending
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/da active
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/ja active Pending
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en active Application Filing
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en active Application Filing
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Application Discontinuation
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/ja active Pending
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/es not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Application Discontinuation
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Application Discontinuation
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/ja active Pending
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
-
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
-
2007
- 2007-10-29 US US11/927,602 patent/US10080785B2/en active Active
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
-
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
-
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/ja active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
-
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
-
2013
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Lifetime
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/ja active Pending
-
2016
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/fr active Active
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
-
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003531590A5 (ja) | ||
JP2003530847A5 (ja) | ||
JP2003530852A5 (ja) | ||
AU2020203352B2 (en) | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use | |
JP4402288B2 (ja) | キメラのインターロイキン−6可溶性受容体/リガンドタンパク質、その類似体およびその使用 | |
US11358997B2 (en) | Fusokines involving cytokines with strongly reduced receptor binding affinities | |
US20200109184A1 (en) | Il-15ralpha sushi domain - il-15 fusion proteins | |
EP3263581B1 (en) | Compositions and methods for immunomodulation in an organism | |
ES2327409T3 (es) | Proteinas de fusion fc mejoradas. | |
JP2004525076A5 (ja) | ||
CN101437847A (zh) | 治疗用靶向细胞因子的抗体 | |
JPH08511000A (ja) | リンパ球におけるキメラサイトカインレセプター | |
CA2438851C (en) | Interleukin-18 mutants, their production and use | |
JP2019518786A (ja) | インターロイキンの組み合せ及びその使用 | |
US20090010872A1 (en) | Chimeric soluble hyper il-11 and use thereof | |
TW201841944A (zh) | 4-1bbl變異體及包含其之融合蛋白 | |
US5972902A (en) | DNA encoding human IL-6 receptor antagonist and protein encoded thereby | |
Poudrier et al. | A soluble form of IL-13 receptor α1 promotes IgG2a and IgG2b production by murine germinal center B cells | |
ES2238690T3 (es) | Muteina il-6. | |
Ozmen et al. | Immunomodulation with Soluble IFN-γ Receptor: Preliminary Study | |
Santos et al. | Obtaining biologically active IL-15 in Escherichia coli |